Targeting cholesterol transport in kidney cancer treatment
Official title: NPC1 as a novel therapeutic target in ccRCC
Funded at Research Inst of Fox Chase Can Ctr · NIH-11037984 · Data updated 2026-11-12
This study is looking at how cholesterol movement in kidney cancer cells might affect how well current treatments work, with the hope of finding better options for patients like you.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst of Fox Chase Can Ctr NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | March 1, 2024 |
| Project end | February 28, 2026 |
| Funding year | 2025 |
| Award (this year) | $263,670 |
| NIH project number | 5R21CA289161-02 |
| Project ID | NIH-11037984 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with clear cell renal cell carcinoma who have not responded well to traditional therapies.
✕Less likely to help
Patients with other subtypes of renal cell carcinoma or those who have not been diagnosed with cancer may not receive benefit from this research.
What this research studies
This research investigates the role of cholesterol transport in clear cell renal cell carcinoma (ccRCC) and how it affects the effectiveness of current cancer therapies. The study focuses on a protein called NPC1, which is involved in the movement of cholesterol within cells. By understanding how ccRCC cells utilize cholesterol from lipoproteins, the research aims to develop new therapeutic strategies that could enhance the efficacy of existing treatments like tyrosine kinase inhibitors. Patients may be able to benefit from more effective treatment options that target this unique metabolic dependency of their cancer cells.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with clear cell renal cell carcinoma.
How similar studies have gone: Other research has shown promising results in targeting metabolic pathways in cancer, suggesting that this approach could be effective.
Where this research is happening
-
Research Inst of Fox Chase Can Ctr
Philadelphia, United States Active
Researchers
- Principal investigator: Kolenko, Vladimir M — Research Inst of Fox Chase Can Ctr
- Study coordinator: Kolenko, Vladimir M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.